Neurocrine Biosciences
NBIX
#1665
Rank
S$16.65 B
Marketcap
S$165.60
Share price
-1.04%
Change (1 day)
26.04%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

P/S ratio for Neurocrine Biosciences (NBIX)

P/S ratio as of April 2026 (TTM): 4.58

According to Neurocrine Biosciences 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.03. At the end of 2025 the company had a P/S ratio of 4.90.

P/S ratio history for Neurocrine Biosciences from 2001 to 2025

PS ratio at the end of each year

Year P/S ratio Change
20254.90-18.24%
20245.99-12.62%
20236.86-11.06%
20227.718.2%
20217.13-16.75%
20208.56-31.97%
201912.6-12.4%
201814.4-66.18%
201742.5-81.05%
2016224-9.2%
2015247
2014N/A-100%
20132162204.11%
20129.3554.16%
20116.07-51.52%
201012.5-69.11%
200940.530.41%
200831.1-78.11%
20071421310.15%
200610.1-46.46%
200518.8-11.08%
200421.152.7%
200313.8-82.15%
200277.6105.49%
200137.8

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Pfizer
PFE
2.48-45.78%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
5.93 29.55%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
12.4 170.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
10.1 121.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
10.4 127.46%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
2.20-51.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
4.38-4.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
12.3 169.37%๐Ÿ‡ฌ๐Ÿ‡ง UK